Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US$256m impairment leads to Aceto loss

Executive Summary

An impairment charge of US$256 million relating to Aceto’s Rising Pharmaceuticals generics business has led the firm to a US$259 million operating loss in its financial third quarter ended 31 March 2018. The goodwill and intangible asset impairment followed “a decline in actual and forecasted revenue and earnings due to persistent adverse conditions in the generics market”, as well as a notification from the US government that 11 products previously purchased from Lucid are not in compliance with country-of-origin requirements of government contracts (Generics bulletin, 9 March 2018, page 4).

You may also be interested in...



Aceto Completes Sale Of Rising Pharmaceuticals

Aceto has completed the divestment of its Rising Pharmaceuticals generics unit, is moving ahead with the disposal of its chemicals business and has disclosed a bonus incentive scheme for its CEO, William Kennally, aimed at securing the maximum value for its assets as part of bankruptcy proceedings.

Aceto Files For Bankruptcy As It Offloads Rising And Chemicals Businesses

Struggling US firm Aceto has filed Chapter 11 bankruptcy petitions at the same time as agreeing to divest its chemicals business assets for US$338 million, with plans to also offload its Rising Pharmaceuticals unit.

Still Can’t Cancel That Gym Membership? FTC Proposes One Negative Option Rule To Rule Them All

The FTC published a notice of proposed rulemaking on 23 March to update its 1973 Negative Option Rule, which has become obsolete vis-à-vis new marketing strategies in today’s digital world. Proposed amendments would clarify, expand and consolidate negative option-related provisions currently dispersed across different FTC laws and regulations.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB000699

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel